ScinoPharm to Provide Contract Manufacturing Service for Melinta ’s Newly-Approved Serious Skin Infections Drug, Baxdela™

ScinoPharm to Provide Contract Manufacturing Service for Melinta ’s Newly-Approved Serious Skin Infections Drug, Baxdela™

2017/8/3

Issued by: ScinoPharm

Issue date: August 03, 2017

 

ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of delafloxacin active pharmaceutical ingredient (“API”) for Melinta’s Baxdela™, a new drug for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) approved by the United States Food and Drug Administration.

ScinoPharm CEO Dr. Yung Fa Chen stated, “ScinoPharm is proud of the productive partnership with Melinta by being its sole API supplier of delafloxacin during Baxdela ’s launch. Beginning from process research through timely development and optimization of long and complicated synthetic routes and manufacturing processes, we have established a win-win partnership. The launching of the product will further improve our momentum in CRAM business.

” In relationship similar to the one with Melinta, ScinoPharm partners with other leading pharmaceutical companies for custom contract services from clinical materials to commercial. So far the company has handled more than 100 NCE projects, with 4 currently in phase III and 6 having already been approved for launch.

Increasing antibiotic resistance is a global medical challenge. Approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult.

 

About ScinoPharm

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities for brand companies as well as APIs for the generic industry. The Company also is aggressively pursuing a vertically integrated, one-stop-shopping service for drug product customers by expanding into the field of sterile oncological injectable formulations. For more information, please visit the Company's website at http://www.scinopharm.com

 

 

CONTACT: Sabrina Wu

Corporate Communications Sr. Manager

TEL: +886-6-508-2869 Mobile

Phone: +886-920-056-385

Email: sabrina.wu@scinopharm.com